Results 271 to 278 of about 30,915 (278)

In Brief: Casgevy for Beta Thalassemia

The Medical Letter on Drugs and Therapeutics
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old with transfusion-dependent beta thalassemia.
openaire   +2 more sources

ALPHA‐ AND BETA‐THALASSEMIA IN THAILAND*

Annals of the New York Academy of Sciences, 1969
S. Pootrakul, P. Wasi, Munsit Sookanek, Supa Na-Nakorn, Pensri Disthasongchan, Vicharn Panich, Malida Pornpatkul   +6 more
openaire   +3 more sources

Breathless: Beta Thalassemia Major

The American Journal of Medicine, 2017
Vassiliki Katsi, Georgios Georgiopoulos, Georgia Vogiatzi, Dimitrios Tousoulis   +3 more
openaire   +3 more sources

HEMOGLOBIN SYNTHESIS IN BETA‐THALASSEMIA

Annals of the New York Academy of Sciences, 1969
A. M. Benson, E. R. Huehns, C. B. Modell
openaire   +3 more sources

Beta-thalassemia and proteolysis. Proteolysis of excess alpha-chains in beta-thalassemia.

The Journal of laboratory and clinical medicine, 1982
Edward R. Burka, Samir K. Ballas
openaire   +3 more sources

Mild Homozygous Beta-Thalassemia

Annals of Internal Medicine, 1966
Paul L. Heller, Charles F. Abildgaard, Vincent Yakulis, Arnold I. Rosenzweig, Donald L. Rucknagel   +4 more
openaire   +3 more sources

[Beta-thalassemia].

La Vie medicale au Canada francais, 1972
openaire   +2 more sources

delta beta-Thalassemia and HPFH.

Birth defects original article series, 1982
S. Ottolenghi, B. Giglioni, R. Taramelli, P. Comi, A.M. Gianni   +4 more
openaire   +2 more sources